Biologic Therapy for Osteoarthritis in Pomona, CA

What I’d check before adding osteoarthritis biologic therapy here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 13% of adults in Pomona have diagnosed diabetes — 1.0 points above the U.S. 12% figure. 17.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick osteoarthritis biologic therapy against that mix.

Where Pomona programs actually stall

• Adult arthritis here is 17.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 17.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in California.
• AHR’s BRFSS diabetes range (Colorado 8.4% to West Virginia 18.4%) is state-level, not city-level. We will not invent a Pomona-specific diabetes rate. Plan from CDC national 12% plus your panel.
• A city under 250k usually means mixed payer mix: Medicare FFS under JE, Medicare Advantage, workers’ comp, and cash-pay sports medicine. One SKU list rarely serves all four without a utilization policy.

Uninsured mix and Medicare CTPs in the same building

JE reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Pomona is 13% or not. PLACES is planning data. The LCD is the claim.

Before the first osteoarthritis biologic therapy shipment